This is a phase Ib/IIa, open-label, dose-escalation, and extension study to evaluate the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma.
Age ≥18 years old, regardless of gender.
Previously treated with at least three drugs (including PI, IMiD, and anti-CD38 antibody), and relapsed/refractory after the most recent anti-MM therapy.
Serum M protein ≥ 0.5g/dL (≥ 5 g/L); or
Urine M protein ≥ 200mg/24 hours; or
Known hypersensitivity to any of the ingredients of this product.
Diagnosis of active plasma cell leukemia.
Diagnosis of systemic light chain amyloidosis.
MM involving the central nervous system.